data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Inhibrx
(NASDAQ:INBX)
13.65
0.78[6.06%]
At close: May 27
13.65
00
After Hours: 5:18PM EDT
Day High/Low12.6 - 13.68
52 Week High/Low11.56 - 47.9
Open / Close13.03 / 13.65
Float / Outstanding23.9M / 39M
Vol / Avg.272.2K / 345.5K
Mkt Cap532.9M
P/E-
50d Avg. Price18.12
Div / Yield-
Payout Ratio-
EPS-0.8
Total Float23.9M

Inhibrx (NASDAQ:INBX), Quotes and News Summary

Inhibrx (NASDAQ: INBX)

Day High/Low12.6 - 13.68
52 Week High/Low11.56 - 47.9
Open / Close13.03 / 13.65
Float / Outstanding23.9M / 39M
Vol / Avg.272.2K / 345.5K
Mkt Cap532.9M
P/E-
50d Avg. Price18.12
Div / Yield-
Payout Ratio-
EPS-0.8
Total Float23.9M
Benzinga - May 17, 2022, 4:49AM
Benzinga - May 16, 2022, 12:32PM
Benzinga - May 16, 2022, 9:06AM
Benzinga - May 9, 2022, 4:35PM
Benzinga - Apr 5, 2022, 4:31PM
Benzinga - Mar 16, 2022, 10:03AM
Benzinga - Mar 2, 2022, 8:21AM
Benzinga - Feb 28, 2022, 4:17PM
Benzinga - Jan 5, 2022, 7:46AM
Benzinga - Jan 4, 2022, 4:06PM
Benzinga - Dec 2, 2021, 6:59AM
Benzinga - Dec 1, 2021, 4:12PM
Benzinga - Nov 10, 2021, 7:31AM
Benzinga - Nov 9, 2021, 4:54PM
Benzinga - Nov 2, 2021, 7:56AM
Benzinga - Oct 12, 2021, 9:00AM
Benzinga - Oct 12, 2021, 8:54AM
Benzinga - Oct 11, 2021, 4:08PM
Benzinga - Sep 21, 2021, 7:13AM
Benzinga - Aug 9, 2021, 5:23PM
load more
Sector: Health Care.Industry: Biotechnology
Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-08
REV
Q1 2022Est.ActualSurprise
EPS-0.800
REV929.000K

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Inhibrx Questions & Answers

Q
How do I buy Inhibrx (INBX) stock?
A

You can purchase shares of Inhibrx (NASDAQ: INBX) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Inhibrx's (INBX) competitors?
Q
What is the target price for Inhibrx (INBX) stock?
A

The latest price target for Inhibrx (NASDAQ: INBX) was reported by SMBC Nikko on Wednesday, March 16, 2022. The analyst firm set a price target for 40.00 expecting INBX to rise to within 12 months (a possible 193.04% upside). 5 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Inhibrx (INBX)?
A

The stock price for Inhibrx (NASDAQ: INBX) is $13.65 last updated May 27, 2022, 8:00 PM UTC.

Q
Does Inhibrx (INBX) pay a dividend?
A

There are no upcoming dividends for Inhibrx.

Q
When is Inhibrx (NASDAQ:INBX) reporting earnings?
A

Inhibrx’s Q2 earnings are confirmed for Monday, August 8, 2022.

Q
Is Inhibrx (INBX) going to split?
A

There is no upcoming split for Inhibrx.

Q
What sector and industry does Inhibrx (INBX) operate in?
A

Inhibrx is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.